Tavilermide: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
| verifiedrevid = |
| verifiedrevid = |
||
| IUPAC_name = 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid |
| IUPAC_name = 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid |
||
| image = |
| image = Tavilermide_structure.png |
||
| width = |
| width = |
||
Revision as of 08:07, 12 October 2015
 | |
| Clinical data | |
|---|---|
| Routes of administration | Eye drop |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H32N6O11 |
| Molar mass | 580.54448 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Tavilermide (INN) (developmental code name MIM-D3) is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.[1][2][3] It was under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and reached phase III clinical trials for this indication, but development appears to have been halted.[1][3][1] Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.[4][2]
See also
References
- ^ a b Meerovitch, Karen; Torkildsen, Gail; Lonsdale, John; Goldfarb, Heidi; Lama, Teresa; Cumberlidge, Garth; Ousler III, George W. (2013). "Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye". Clinical Ophthalmology: 1275. doi:10.2147/OPTH.S44688. ISSN 1177-5483.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Jain, Pooja; Li, Ruihong; Lama, Teresa; Saragovi, H. Uri; Cumberlidge, Garth; Meerovitch, Karen (2011). "An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye". Experimental Eye Research. 93 (4): 503–512. doi:10.1016/j.exer.2011.06.014. ISSN 0014-4835.
- ^ a b Vickers, Laura A.; Gupta, Preeya K. (2015). "The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline". Ophthalmology and Therapy. doi:10.1007/s40123-015-0038-y. ISSN 2193-8245.
- ^ Chang EE, Goldberg JL (2012). "Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement". Ophthalmology. 119 (5): 979–86. doi:10.1016/j.ophtha.2011.11.003. PMC 3343191. PMID 22349567.
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |